

LEGISLATIVE ACTION

Senate House

Comm: RCS 04/25/2013

The Committee on Appropriations (Grimsley) recommended the following:

Senate Amendment (with title amendment)

Delete lines 58 - 223

and insert:

2 3

4

5

6

8

9 10

11

12

Section 1. Section 456.44, Florida Statutes, is amended to read:

456.44 Controlled substance prescribing.-

- (1) DEFINITIONS.—
- (a) "Addiction medicine specialist" means a board-certified psychiatrist with a subspecialty certification in addiction medicine or who is eligible for such subspecialty certification in addiction medicine, an addiction medicine physician certified

14 15

16 17

18

19

20 2.1

22

23

24

25

26

27

28

29

30

31

32 33

34 35

36

37

38

39

40

41



or eligible for certification by the American Society of Addiction Medicine, or an osteopathic physician who holds a certificate of added qualification in Addiction Medicine through the American Osteopathic Association.

- (b) "Adverse incident" means any incident set forth in s. 458.351(4)(a)-(e) or s. 459.026(4)(a)-(e).
- (c) "Board-certified pain management physician" means a physician who possesses board certification in pain medicine by the American Board of Pain Medicine, board certification by the American Board of Interventional Pain Physicians, or board certification or subcertification in pain management or pain medicine by a specialty board recognized by the American Association of Physician Specialists or the American Board of Medical Specialties or an osteopathic physician who holds a certificate in Pain Management by the American Osteopathic Association.
- (d) "Board eligible" means successful completion of an anesthesia, physical medicine and rehabilitation, rheumatology, or neurology residency program approved by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association for a period of 6 years from successful completion of such residency program.
- (e) "Chronic nonmalignant pain" means pain unrelated to cancer which persists beyond the usual course of disease or the injury that is the cause of the pain or more than 90 days after surgery.
- (f) "Mental health addiction facility" means a facility licensed under chapter 394 or chapter 397.
 - (2) REGISTRATION.—Effective January 1, 2012, A physician

43

44

45 46

47

48

49

50

51

52

53

54

55

56 57

58

59

60

61

62

63

64 65

66

67 68

69 70



licensed under chapter 458, chapter 459, chapter 461, or chapter 466 who prescribes more than a 30-day supply of any controlled substance, listed in Schedule II, Schedule III, or Schedule IV as defined in s. 893.03, over a 6-month period to any one patient for the treatment of chronic nonmalignant pain, must:

- (a) Designate himself or herself as a controlled substance prescribing practitioner on the physician's practitioner profile.
- (b) Comply with the requirements of this section and applicable board rules.
- (3) STANDARDS OF PRACTICE.—The standards of practice in this section do not supersede the level of care, skill, and treatment recognized in general law related to health care licensure.
- (a) A complete medical history and a physical examination must be conducted before beginning any treatment and must be documented in the medical record. The exact components of the physical examination shall be left to the judgment of the clinician who is expected to perform a physical examination proportionate to the diagnosis that justifies a treatment. The medical record must, at a minimum, document the nature and intensity of the pain, current and past treatments for pain, underlying or coexisting diseases or conditions, the effect of the pain on physical and psychological function, a review of previous medical records, previous diagnostic studies, and history of alcohol and substance abuse. The medical record shall also document the presence of one or more recognized medical indications for the use of a controlled substance. Each registrant must develop a written plan for assessing each

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 89

90

91

92

93

94

95

96

97

98 99



patient's risk of aberrant drug-related behavior, which may include patient drug testing. Registrants must assess each patient's risk for aberrant drug-related behavior and monitor that risk on an ongoing basis in accordance with the plan.

(b) Before or during a new patient's visit for services for the treatment of pain at a pain-management clinic registered under s. 458.3265 or s. 459.0137, a physician shall consult the prescription drug monitoring program database provided under s. 893.055(2)(a) before prescribing a controlled substance listed in Schedule II or Schedule III in s. 893.03. The physician may designate an agent under his or her supervision to consult the database. The Board of Medicine under chapter 458 and the Board of Osteopathic Medicine under chapter 459 shall adopt rules to establish a penalty for a physician who does not comply with this subsection.

(c) (b) Each registrant must develop a written individualized treatment plan for each patient. The treatment plan shall state objectives that will be used to determine treatment success, such as pain relief and improved physical and psychosocial function, and shall indicate if any further diagnostic evaluations or other treatments are planned. After treatment begins, the physician shall adjust drug therapy to the individual medical needs of each patient. Other treatment modalities, including a rehabilitation program, shall be considered depending on the etiology of the pain and the extent to which the pain is associated with physical and psychosocial impairment. The interdisciplinary nature of the treatment plan shall be documented.

(d) (c) The physician shall discuss the risks and benefits

101 102

103

104 105

106

107

108

109

110 111

112

113

114 115

116

117

118 119

120

121

122

123

124

125

126

127 128



of the use of controlled substances, including the risks of abuse and addiction, as well as physical dependence and its consequences, with the patient, persons designated by the patient, or the patient's surrogate or quardian if the patient is incompetent. The physician shall use a written controlled substance agreement between the physician and the patient outlining the patient's responsibilities, including, but not limited to:

- 1. Number and frequency of controlled substance prescriptions and refills.
- 2. Patient compliance and reasons for which drug therapy may be discontinued, such as a violation of the agreement.
- 3. An agreement that controlled substances for the treatment of chronic nonmalignant pain shall be prescribed by a single treating physician unless otherwise authorized by the treating physician and documented in the medical record.
- (e) (d) The patient shall be seen by the physician at regular intervals, not to exceed 3 months, to assess the efficacy of treatment, ensure that controlled substance therapy remains indicated, evaluate the patient's progress toward treatment objectives, consider adverse drug effects, and review the etiology of the pain. Continuation or modification of therapy shall depend on the physician's evaluation of the patient's progress. If treatment goals are not being achieved, despite medication adjustments, the physician shall reevaluate the appropriateness of continued treatment. The physician shall monitor patient compliance in medication usage, related treatment plans, controlled substance agreements, and indications of substance abuse or diversion at a minimum of 3-



month intervals.

129

130

131

132

133 134

135

136

137

138 139

140

141 142

143

144

145

146 147

148 149

150

151

152 153

154

155

156

157

(f) (e) The physician shall refer the patient as necessary for additional evaluation and treatment in order to achieve treatment objectives. Special attention shall be given to those patients who are at risk for misusing their medications and those whose living arrangements pose a risk for medication misuse or diversion. The management of pain in patients with a history of substance abuse or with a comorbid psychiatric disorder requires extra care, monitoring, and documentation and requires consultation with or referral to an addiction medicine specialist or psychiatrist.

- (g) (f) A physician registered under this section must maintain accurate, current, and complete records that are accessible and readily available for review and comply with the requirements of this section, the applicable practice act, and applicable board rules. The medical records must include, but are not limited to:
- 1. The complete medical history and a physical examination, including history of drug abuse or dependence.
 - 2. Diagnostic, therapeutic, and laboratory results.
 - 3. Evaluations and consultations.
 - 4. Treatment objectives.
 - 5. Discussion of risks and benefits.
 - 6. Treatments.
- 7. Medications, including date, type, dosage, and quantity prescribed.
 - 8. Instructions and agreements.
 - 9. Periodic reviews.
 - 10. Results of any drug testing.



- 11. A photocopy of the patient's government-issued photo identification.
- 12. If a written prescription for a controlled substance is given to the patient, a duplicate of the prescription.
- 13. The physician's full name presented in a legible manner.

(h) (g) Patients with signs or symptoms of substance abuse shall be immediately referred to a board-certified pain management physician, an addiction medicine specialist, or a mental health addiction facility as it pertains to drug abuse or addiction unless the physician is board-certified or boardeligible in pain management. Throughout the period of time before receiving the consultant's report, a prescribing physician shall clearly and completely document medical justification for continued treatment with controlled substances and those steps taken to ensure medically appropriate use of controlled substances by the patient. Upon receipt of the consultant's written report, the prescribing physician shall incorporate the consultant's recommendations for continuing, modifying, or discontinuing controlled substance therapy. The resulting changes in treatment shall be specifically documented in the patient's medical record. Evidence or behavioral indications of diversion shall be followed by discontinuation of controlled substance therapy, and the patient shall be discharged, and all results of testing and actions taken by the physician shall be documented in the patient's medical record.

183 184 185

186

158

159

160

161

162

163

164

165

166

167

168

169

170 171

172

173

174

175

176

177

178

179

180

181

182

This section subsection does not apply to a board-eligible or board-certified anesthesiologist, physiatrist, rheumatologist,



or neurologist, or to a board-certified physician who has surgical privileges at a hospital or ambulatory surgery center and primarily provides surgical services. This section subsection does not apply to a board-eligible or board-certified medical specialist who has also completed a fellowship in pain medicine approved by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association, or who is board eligible or board certified in pain medicine by the American Board of Pain Medicine or a board approved by the American Board of Medical Specialties or the American Osteopathic Association and performs interventional pain procedures of the type routinely billed using surgical codes. This section subsection does not apply to a physician who prescribes medically necessary controlled substances for a patient during an inpatient stay in a hospital licensed under chapter 395 or to a resident in a facility licensed under part II of chapter 400. This section does not apply to a physician licensed under chapter 458 or chapter 459 who writes fewer than 50 prescriptions for a controlled substance for all of his or her patients during a 1-year period.

206 207

210

212

213

187

188

189 190

191 192

193

194

195

196

197

198

199 200

201

202

203

204

205

========= T I T L E A M E N D M E N T ========== 208 209

And the title is amended as follows:

Delete line 8

and insert: 211

> substances; authorizing the the Board of Medicine and the Board of Osteopathic Medicine to adopt